{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:02:30Z","timestamp":1785074550873,"version":"3.55.0"},"reference-count":218,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189635","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:42:26Z","timestamp":1781332946000},"page":"189635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pivotal role of PD-1\/PD-L1 as an immune checkpoint in lymphoma and solid tumor: Cellular organization, clinical implications & the potential of small molecule inhibitors"],"prefix":"10.1016","volume":"1881","author":[{"given":"Pragya","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Sargam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha Pratim","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189635_bb0005","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41598-018-20325-0","article-title":"Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry","volume":"8","author":"Tavares","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0010","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ijc.34163","article-title":"Global patterns of non-Hodgkin lymphoma in 2020","volume":"151","author":"Mafra","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fonc.2017.00067","article-title":"Update on programmed Death-1 and programmed death-ligand 1 inhibition in the treatment of advanced or metastatic non-small cell lung cancer","volume":"7","author":"Iafolla","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.bbcan.2026.189635_bb0025","first-page":"1134","article-title":"The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma","volume":"23","author":"Ruan","year":"2021","journal-title":"Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"key":"10.1016\/j.bbcan.2026.189635_bb0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/ph8030607","article-title":"Novel targeted agents in Hodgkin and non-Hodgkin lymphoma therapy","volume":"8","author":"Grover","year":"2015","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbcan.2026.189635_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107870","article-title":"Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer","volume":"227","author":"Islam","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0040","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.2147\/OTT.S242018","article-title":"A review of chimeric antigen receptor T-cell therapy for myeloma and lymphoma","volume":"14","author":"Atrash","year":"2021","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1420920","article-title":"Immune checkpoint inhibitors targeting PD-1\/PD-L1 in the treatment of human lymphomas","volume":"14","author":"Ribatti","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0050","first-page":"529","article-title":"Therapeutic targeting of immune checkpoints with small molecule inhibitors","volume":"11","author":"Smith","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189635_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0070","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2020.1830056","article-title":"Pembrolizumab for the treatment of Hodgkin lymphoma","volume":"20","author":"Al Hadidi","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0075","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/ijms23031501","article-title":"Molecular aspects of resistance to immunotherapies-advances in understanding and Management of Diffuse Large B-cell lymphoma","volume":"23","author":"Kusowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189635_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12935-021-01946-4","article-title":"Small molecule inhibitors against PD-1\/PD-L1 immune checkpoints and current methodologies for their development: a review","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189635_bb0095","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 Axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0100","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119813","article-title":"Advance investigation on synthetic small-molecule inhibitors targeting PD-1\/PD-L1 signaling pathway","volume":"282","author":"Awadasseid","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2026.189635_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/cancers14010109","article-title":"Comparative analysis of predictive biomarkers for PD-1\/PD-L1 inhibitors in cancers: developments and challenges","volume":"14","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3892\/mmr.2021.12001","article-title":"A combination of PD-1\/PD-L1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy","volume":"23","author":"Kong","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S284988","article-title":"Immune checkpoint blockade for the treatment of Hodgkin lymphoma","volume":"11","author":"Lin","year":"2022","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0125","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0135","first-page":"1508","article-title":"PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma","volume":"4","author":"Wartewig","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189635_bb0140","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2026.189635_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbcan.2026.189635_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0155","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3892\/or.2024.8792","article-title":"Histone deacetylase inhibitor and PD-1 blockade synergistically inhibit B-cell lymphoma progression in mice model by promoting T-cell infiltration and apoptosis","volume":"52","author":"Wang","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0180","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","article-title":"ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome","volume":"41","author":"Parry","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189635_bb0185","article-title":"Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154008","article-title":"Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system","volume":"239","author":"Liu","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2026.189635_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.673912","article-title":"CMTM6-deficient monocytes in ANCA-associated Vasculitis fail to present the immune checkpoint PD-L1","volume":"12","author":"Zeisbrich","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0200","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0205","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/2326-6066.CIR-21-0493","article-title":"Monitoring PD-1 phosphorylation to evaluate PD-1 signaling during antitumor immune responses","volume":"9","author":"Bu","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.humpath.2021.07.011","article-title":"Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan","volume":"116","author":"Iwafuchi","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0215","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0220","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00262-020-02575-y","article-title":"In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy","volume":"69","author":"Marcelis","year":"2020","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.bbcan.2026.189635_bb0225","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1626653","article-title":"High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system","volume":"8","author":"Kim","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2026.189635_bb0230","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.2018.197194","article-title":"PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma","volume":"103","author":"Pollari","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2026.189635_bb0235","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jcyt.2022.07.012","article-title":"\u0393c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1","volume":"24","author":"Singh","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbcan.2026.189635_bb0240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41590-022-01373-1","article-title":"Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells","volume":"24","author":"Kim","year":"2023","journal-title":"Nat. Immunol."},{"issue":"196","key":"10.1016\/j.bbcan.2026.189635_bb0245","first-page":"2431","article-title":"Genetic and epigenetic regulation of PD-1 expression","volume":"2016","author":"Bally","year":"1950","journal-title":"J. Immunol. Baltim. Md."},{"key":"10.1016\/j.bbcan.2026.189635_bb0250","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbcan.2026.189635_bb0260","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189635_bb0265","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0270","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cam4.2097","article-title":"Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0275","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/bloodadvances.2023011687","article-title":"Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC\/BCL2 vs patients with DLBCL NOS","volume":"8","author":"de Jonge","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.imlet.2020.12.005","article-title":"Dynamics of TIGIT and PD-1 expression on NK cells during the course of normal pregnancy","volume":"230","author":"Wang","year":"2021","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbcan.2026.189635_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886931","article-title":"Burgeoning exploration of the role of natural killer cells in anti-PD-1\/PD-L1 therapy","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0295","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189635_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004695","article-title":"Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment","volume":"10","author":"Ac\u00farcio","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/biology12091163","article-title":"A story of kinases and adaptors: the role of Lck, ZAP-70 and LAT in switch panel governing T-cell development and activation","volume":"12","author":"Fern\u00e1ndez-Aguilar","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.bbcan.2026.189635_bb0310","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.apsb.2021.03.010","article-title":"PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2026.189635_bb0315","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189635_bb0320","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bbcan.2026.189635_bb0325","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","article-title":"Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0330","article-title":"The complex role of regulatory T cells in immunity and aging","volume":"11","author":"Rocamora-Reverte","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0335","article-title":"Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition","volume":"41","author":"Singh","year":"2024","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"10.1016\/j.bbcan.2026.189635_bb0340","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0350","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0355","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1002\/jcp.29491","article-title":"Cytokines as potential combination agents with PD-1\/PD-L1 blockade for cancer treatment","volume":"235","author":"Rahimi Kalateh Shah Mohammad","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0360","first-page":"303","article-title":"Immune checkpoint inhibitors in malignant lymphoma: advances and perspectives","volume":"32","author":"Lin","year":"2020","journal-title":"Chin. J. Cancer Res. Chung-Kuo Yen Cheng Yen Chiu"},{"key":"10.1016\/j.bbcan.2026.189635_bb0365","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11912-020-00928-5","article-title":"Spectrum and clinical activity of PD-1\/PD-L1 inhibitors: regulatory approval and under development","volume":"22","author":"Oliveira","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0375","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy","volume":"14","author":"Ai","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020214","article-title":"Immune-checkpoint inhibitors in B-cell lymphoma","volume":"13","author":"Armengol","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0385","article-title":"Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: A promising breakthrough in cancer therapeutics","volume":"15","author":"Abaza","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bbcan.2026.189635_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100825","article-title":"Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1\/PD-1 axis","volume":"13","author":"Sun","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745939","article-title":"Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation","volume":"12","author":"Sierra","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0400","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/OTT.S368408","article-title":"From co-stimulation to co-inhibition: A continuum of immunotherapy care toward long-term survival in melanoma","volume":"16","author":"Simonetti","year":"2023","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100325","article-title":"Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)","volume":"6","author":"Nakamura","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb0415","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2147\/OTT.S109453","article-title":"Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer","volume":"10","author":"Aydin","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10020032","article-title":"Tackling cancer resistance by immunotherapy: updated clinical impact and safety of PD-1\/PD-L1 inhibitors","volume":"10","author":"Abdin","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0425","first-page":"357","article-title":"Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway","volume":"7","author":"Momtaz","year":"2014","journal-title":"Pharmacogenom. Pers. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0430","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3389\/fimmu.2019.01337","article-title":"Recent findings in the regulation of programmed death ligand 1 expression","volume":"10","author":"Shen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0440","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184683","article-title":"The PD-1\/PD-L1 checkpoint in normal germinal centers and diffuse large B-cell lymphomas","volume":"13","author":"Garcia-Lacarte","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0455","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood.2023021283","article-title":"Tackling PD1i resistance in Hodgkin lymphoma","volume":"142","author":"Collins","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189635_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100977","article-title":"Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter\u2019s transformation","volume":"14","author":"Hodkinson","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071536","article-title":"Mechanisms of immune evasion in acute lymphoblastic leukemia","volume":"13","author":"Pastorczak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107870","article-title":"PD-1 and PD-L1 inhibitors foster the progression of adult T-cell leukemia\/lymphoma","volume":"98","author":"Jalili-Nik","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0480","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.bbcan.2026.189635_bb0485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.bbcan.2026.189635_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26613","article-title":"Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors","volume":"64","author":"Pinto","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0495","article-title":"Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbcan.2026.189635_bb0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438111","article-title":"Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy","volume":"7","author":"Yue","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2026.189635_bb0505","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0510","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118297","article-title":"PD-1\/PD-L1 axis importance and tumor microenvironment immune cells","volume":"259","author":"Lotfinejad","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2026.189635_bb0520","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094766","article-title":"Molecular mechanism of small-molecule inhibitors in blocking the PD-1\/PD-L1 pathway through PD-L1 dimerization","volume":"22","author":"Guo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189635_bb0530","doi-asserted-by":"crossref","first-page":"293","DOI":"10.31083\/j.fbl2908293","article-title":"Effector functions of dendritic cells in cancer: role of cytotoxicity and growth inhibition","volume":"29","author":"Chaudhary","year":"2024","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.bbcan.2026.189635_bb0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0540","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","article-title":"PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell-driven antitumor immunity","volume":"24","author":"Buchan","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0545","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-020-02654-0","article-title":"Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma","volume":"70","author":"Chu","year":"2021","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.bbcan.2026.189635_bb0550","first-page":"89","article-title":"Comparison of antitumor effects of combinations of immune checkpoint inhibitors with dendritic cells Intratumorally injected into irradiated mouse adenocarcinoma","volume":"48","author":"Park","year":"2025","journal-title":"J. Immunother. Hagerstown Md 1997"},{"key":"10.1016\/j.bbcan.2026.189635_bb0555","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","article-title":"Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189635_bb0560","article-title":"The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0565","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2494995","article-title":"Avelumab induces greater fc-fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab","volume":"14","author":"Osborne","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2026.189635_bb0570","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189635_bb0575","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051037","article-title":"Type I and II interferons in the anti-tumor immune response","volume":"13","author":"Fenton","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0585","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0590","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0600","article-title":"The application of Interleukin-2 family cytokines in tumor immunotherapy research","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0605","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","article-title":"Neuromodulation by the immune system: a focus on cytokines","volume":"21","author":"Salvador","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0610","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0615","article-title":"Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo","volume":"37","author":"Chen","year":"2018","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bbcan.2026.189635_bb0620","doi-asserted-by":"crossref","first-page":"ra94","DOI":"10.1126\/scisignal.aaf3957","article-title":"Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells","volume":"9","author":"Li","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2026.189635_bb0625","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-03138-5","article-title":"Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression","volume":"71","author":"Huang","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.bbcan.2026.189635_bb0630","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4155\/fmc-2021-0256","article-title":"Advances of biphenyl small-molecule inhibitors targeting PD-1\/PD-L1 interaction in cancer immunotherapy","volume":"14","author":"Chen","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113170","article-title":"Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1\/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation","volume":"213","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0640","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13543776.2018.1512706","article-title":"A patent review on PD-1\/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)","volume":"28","author":"Shaabani","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bbcan.2026.189635_bb0645","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13543776.2022.2045276","article-title":"Small molecule inhibitors of programmed cell death ligand 1 (PD-L1): A patent review (2019-2021)","volume":"32","author":"Deng","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bbcan.2026.189635_bb0650","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189635_bb0655","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0660","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189635_bb0665","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/acsmedchemlett.6c00048","article-title":"Design, synthesis and biological evaluation of Oxadiazole-biphenyl derivatives as small molecule inhibitors targeting PD-1\/PD-L1 immune checkpoint","volume":"17","author":"Xie","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189635_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109477","article-title":"Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo","volume":"170","author":"Zhang","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118366","article-title":"Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1\/programmed cell death-ligand 1 (PD-1\/PD-L1) interaction","volume":"130","author":"Yang","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0680","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1021\/acsmedchemlett.5c00423","article-title":"Discovery of Pyrazole-containing 4-Arylindolines as potent small-molecule inhibitors of the programmed cell Death-1\/programmed cell death-ligand 1 interaction","volume":"16","author":"Deng","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189635_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116622","article-title":"Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1\/PD-l1 interaction","volume":"275","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0690","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/acsmedchemlett.4c00042","article-title":"Nonsymmetrically substituted 1,1\u2032-biphenyl-based small molecule inhibitors of the PD-1\/PD-L1 interaction","volume":"15","author":"Hec-Ga\u0142\u0105zka","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189635_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107376","article-title":"Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1\/PD-L1 interaction","volume":"147","author":"Xu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0705","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1831153","article-title":"Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export","volume":"9","author":"Chen","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbcan.2026.189635_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113001","article-title":"Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1\/ programmed cell death-ligand 1 (PD-1\/PD-L1) interaction","volume":"211","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105034","article-title":"Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1\/PD-L1 interaction","volume":"114","author":"Dai","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113998","article-title":"Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1\/programmed cell death-ligand 1 (PD-1\/PD-L1) interaction","volume":"229","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0725","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: A potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189635_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106740","article-title":"Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1\/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy","volume":"139","author":"Yang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0735","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/acsmedchemlett.4c00014","article-title":"Design, synthesis, and evaluation of 8-(o -Tolyl)quinazoline derivatives as small-molecule PD-1\/PD-L1 antagonists","volume":"15","author":"Wu","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189635_bb0740","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/acs.jmedchem.4c00102","article-title":"Discovery of novel PD-L1 small-molecular inhibitors with potent In vivo anti-tumor immune activity","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0745","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1021\/acs.jmedchem.0c00574","article-title":"Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1\/programmed cell death\u2013ligand 1 interaction as potential anticancer agents","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0750","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1021\/acs.jmedchem.4c00128","article-title":"Discovery of novel small-molecule-based potential PD-L1\/EGFR dual inhibitors with high druggability for glioblastoma immunotherapy","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0755","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-24-3691","article-title":"JAB-3312, a potent allosteric SHP2 inhibitor that enhances the efficacy of RTK\/RAS\/MAPK and PD-1 blockade therapies","volume":"31","author":"Kang","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117966","article-title":"Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment","volume":"297","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0765","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1021\/acs.jmedchem.3c00264","article-title":"Novel 4-Arylindolines containing a Pyrido[3,2- d ]pyrimidine moiety as the programmed cell Death-1\/programmed cell death-ligand 1 interaction inhibitors for tumor immunotherapy","volume":"66","author":"Meng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0770","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.1c00010","article-title":"Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell Death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0775","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D3MD00655G","article-title":"Progress in small-molecule inhibitors targeting PD-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0780","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1021\/acs.jmedchem.5c02586","article-title":"Coupling PD-L1 inhibition and lysosomal degradation: innovative anti-PD-L1 peptides for NSCLC immunotherapy","volume":"69","author":"Merlino","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189635_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130458","article-title":"Discovery of bioactive natural products of microbial origin as inhibitors of the PD-1\/PD-L1 protein-protein interaction","volume":"264","author":"Domingo-Contreras","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0790","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41467-020-20723-x","article-title":"Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189635_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115022","article-title":"Achievements applications and future of nanomaterials in cancer immunotherapy","volume":"161","author":"Zhu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0800","article-title":"Nanomaterials-guided metabolism-immunity crosstalk for boosting Cancer immunotherapy","author":"Li","year":"2026","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bbcan.2026.189635_bb0805","article-title":"Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors","volume":"17","author":"Zhao","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0810","doi-asserted-by":"crossref","first-page":"64592","DOI":"10.1021\/acsami.4c15342","article-title":"pH and redox dual-responsive nanoparticle with enhanced dendritic cell maturation for Cancer therapy","volume":"16","author":"Yun","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbcan.2026.189635_bb0815","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","article-title":"Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0820","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/IJN.S285999","article-title":"Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors","volume":"16","author":"Qi","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2026.189635_bb0825","article-title":"A local and low-dose chemotherapy\/autophagy-enhancing regimen treatment markedly inhibited the growth of established solid tumors through a systemic antitumor immune response","volume":"11","author":"Yuan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2021.102205","article-title":"A review of advanced nanoformulations in phototherapy for cancer therapeutics","volume":"33","author":"Hak","year":"2021","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194893","article-title":"Anti-PD-1\/anti-PD-L1 drugs and radiation therapy: combinations and optimization strategies","volume":"13","author":"Boustani","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0840","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jconrel.2021.03.038","article-title":"Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation","volume":"333","author":"Kim","year":"2021","journal-title":"J. Control Rel. Off. J. Control Rel. Soc."},{"key":"10.1016\/j.bbcan.2026.189635_bb0845","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1021\/acs.molpharmaceut.1c00050","article-title":"Targeting PD-1 in CD8+ T cells with a biomimetic Bilirubin-5-fluoro-2-deoxyuridine-bovine serum albumin Nanoconstruct for effective chemotherapy against experimental lymphoma","volume":"18","author":"Srivastava","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2026.189635_bb0850","doi-asserted-by":"crossref","first-page":"53577","DOI":"10.1021\/acsami.4c12821","article-title":"Dendritic cell-targeted nanoparticles enhance T cell activation and antitumor immune responses by boosting antigen presentation and blocking PD-L1 pathways","volume":"16","author":"Srivastava","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbcan.2026.189635_bb0855","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/IJN.S295565","article-title":"Cancer cell membrane camouflaged mesoporous silica nanoparticles combined with immune checkpoint blockade for regulating tumor microenvironment and enhancing antitumor therapy","volume":"16","author":"Zhao","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2026.189635_bb0860","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/nnm-2017-0296","article-title":"Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma","volume":"13","author":"Zheng","year":"2018","journal-title":"Nanomed"},{"key":"10.1016\/j.bbcan.2026.189635_bb0865","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0870","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189635_bb0875","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189635_bb0880","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fphar.2019.00387","article-title":"Safety and efficacy of anti-PD-1 monoclonal antibodies in patients with relapsed or refractory lymphoma: a meta-analysis of prospective clinic trails","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0885","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0890","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bbcan.2026.189635_bb0895","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189635_bb0900","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0905","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of Nivolumab plus Ipilimumab vs Nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial","volume":"9","author":"Harrington","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0910","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0915","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0920","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose Decitabine to anti\u2013PD-1 antibody Camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0925","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010783","article-title":"JAK3A573V and JAK3M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3\/PD-L1 pathway","volume":"13","author":"Lou","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0930","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647733","article-title":"Combination therapy with anti-PD-1 or PD-1 antibody alone in Asian pediatric patients with relapsed or refractory Cancer","volume":"12","author":"Que","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.01.020","article-title":"Dose escalation and expansion (phase Ia\/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma","volume":"148","author":"Liu","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0940","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1182\/bloodadvances.2025016298","article-title":"Nivolumab in combination with R-CHOP for treatment-na\u00efve diffuse large B-cell lymphoma: an evaluation of safety and efficacy","volume":"9","author":"Odetola","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0945","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12885-021-09028-4","article-title":"High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in relapsed\/refractory classical Hodgkin lymphoma","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0950","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","article-title":"Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma","volume":"9","author":"Xiong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb0955","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189635_bb0960","article-title":"Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicenter, phase II study","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0965","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0970","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb0975","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002863","article-title":"First-in-human phase I\/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas","volume":"9","author":"Piha-Paul","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0980","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-024-01627-5","article-title":"Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial","volume":"17","author":"Bi","year":"2024","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0985","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial","volume":"18","author":"Chen","year":"2025","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb0990","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007364","article-title":"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors","volume":"12","author":"Khushalani","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb0995","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb1000","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009662","article-title":"Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial","volume":"12","author":"Tang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb1005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011651","article-title":"Phase 1b\/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors","volume":"13","author":"Milhem","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb1010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-025-02281-0","article-title":"Multicenter phase 1\/2 study of onatasertib, a dual TORC1\/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors","volume":"10","author":"Shu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb1015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189635_bb1020","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","article-title":"Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"14","author":"Yuan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189635_bb1025","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-025-02990-x","article-title":"First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors","volume":"132","author":"Day","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189635_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102217","article-title":"Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors","volume":"9","author":"Perez","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102387","article-title":"A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)","volume":"9","author":"Di Giacomo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104536","article-title":"A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer","volume":"10","author":"Gouda","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105051","article-title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies","volume":"10","author":"Janku","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105840","article-title":"MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer","volume":"10","author":"Borcoman","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189635_bb1055","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb1060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb1065","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with Durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189635_bb1070","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with Nivolumab in advanced anti\u2013PD-1\u2013failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189635_bb1075","article-title":"Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1\/CTLA-4 dual blocker in advanced solid tumors\u2014A phase 1\/1b study","volume":"6","author":"Ma","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189635_bb1080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/2159-8290.CD-20-0419","article-title":"Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade","volume":"11","author":"Arbour","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189635_bb1085","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.24.00133","article-title":"Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in advanced non\u2013small cell lung cancer","author":"Sako","year":"2024","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.bbcan.2026.189635_bb1090","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.23.00207","article-title":"Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data","author":"Lippenszky","year":"2024","journal-title":"JCO Clin. Cancer Inform."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:34:57Z","timestamp":1785072897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":218,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26001071"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189635","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pivotal role of PD-1\/PD-L1 as an immune checkpoint in lymphoma and solid tumor: Cellular organization, clinical implications & the potential of small molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189635"}}